Fiche centre
University Clinical Center NIS
Niš — Serbia
Essais liés12clinical trials
VilleNišlocalisation
PaysSerbialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06540833
Essais cliniques associés
12| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Soticlestat | Épilepsie | Phase 3 | NCT04940624 | A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome | COMPLETED |
| Soticlestat | Épilepsie | Phase 3 | NCT05163314 | A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or Lennox-Gastaut Syndrome | TERMINATED |
| Soticlestat | Épilepsie | Phase 3 | NCT04938427 | A Study of Soticlestat as an Add-on Therapy in Children, Teenagers, and Adults With Lennox-Gastaut Syndrome | COMPLETED |
| ACP-204 | Alzheimer | Phase 2/3 | NCT06159673 | ACP-204 in Adults With Alzheimer's Disease Psychosis | RECRUITING |
| Clemizole HCl | Épilepsie | Phase 3 | NCT05066217 | An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome | RECRUITING |
| ITI-1284 | Alzheimer | Phase 2 | NCT06651567 | A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | RECRUITING |
| ITI-1284 | Alzheimer | Phase 2 | NCT06540833 | A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | RECRUITING |
| ACP-204 | Alzheimer | Phase 3 | NCT06194799 | ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study | ENROLLING_BY_INVITATION |
| Eptinezumab | Migraine | Phase 3 | NCT05897320 | PROSPECT-1 — A Study of Eptinezumab in Pediatric Participants With Episodic Migraine | RECRUITING |
| Eptinezumab | Migraine | Phase 3 | NCT05164172 | REJOIN — A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine | RECRUITING |
| Efgartigimod PH20 SC | Myasthénie | Phase 3 | NCT06558279 | ADAPT oculus — A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | ACTIVE_NOT_RECRUITING |
| Ponesimod | SEP | Phase 3 | NCT03232073 | Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis | COMPLETED |